Stockscreener 앱 받기
1.96
7.55%
-0.16
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
Adc therapeutics sees $609,000 in stock purchases by Redmile - Investing.com South Africa
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
HC Wainwright Reiterates “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics stock plunges 36% amid Zynlonta data release (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics shares drop after trial results By Investing.com - Investing.com South Africa
ADC Therapeutics shares drop after trial results - Investing.com
Adc Therapeutics Sa Announces Positive Initial Data from Lotis-7 Clinical Trial Evaluating Zynlonta®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Teeters on Trial Data - Baystreet.ca
ADC Therapeutics SA Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Nasdaq
ADC Therapeutics' ZYNLONTA Shows Remarkable 94% Response Rate in Lymphoma Trial Data - StockTitan
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Quantisnow
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial - Marketscreener.com
Adc Therapeutics Sa Announces the Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating Zynlonta®? in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Marketscreener.com
ADC Therapeutics' ZYNLONTA Shows Breakthrough 97% Response Rate in Lymphoma Clinical Trials - StockTitan
Insider Selling: ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Sells 25,352 Shares of Stock - MarketBeat
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clini - GuruFocus.com
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Raised by Redmile Group LLC - MarketBeat
Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324) - Yahoo Finance
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GuruFocus.com
ADC Therapeutics Grants 34,900 Share Options to New Employees in Inducement Plan | ADCT Stock News - StockTitan
ADC Therapeutics to Host Third Quarter 2024 Financial Results Co - GuruFocus.com
ADC Therapeutics to Present at November Investor Conferences - GuruFocus.com
Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More - Yahoo Finance UK
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Fin - GuruFocus.com
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus.com
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates - MSN
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 9.7% - MarketBeat
Head to Head Comparison: ADC Therapeutics (NYSE:ADCT) & Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Redmile Group, LLC Reduces Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics shareholders approve capital increase - Investing.com India
ADC Therapeutics shareholders approve capital increase By Investing.com - Investing.com UK
Prosight Management, LP Expands Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - Insider Monkey
ADC Therapeutics : Guggenheim Healthcare Innovation Conference - Marketscreener.com
Analysts Set ADC Therapeutics SA (NYSE:ADCT) PT at $8.25 - Defense World
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% UpsideHere's Why - AOL
ADC Therapeutics SA (NYSE:ADCT) Receives $8.25 Average Price Target from Analysts - MarketBeat
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Marketscreener.com
ADC Therapeutics (NYSE:ADCT) Now Covered by Analysts at Stephens - MarketBeat
ADC Therapeutics SA (ADCT) Quarterly 10-Q Report - Quartzy
2.88%
2.65%
자본화:
|
볼륨(24시간):